Tumor drug response testing
Live chemoresponse marker
Identify effective treatments for your GYN cancer patients.
Treatment guidelines are a tool to help direct therapy for many types of cancer, but there are times when these guidelines fall short. What do you do when patients are refractory to initial treatment, have rare tumor types or tumors with no established protocol, or suffer from recurrent cancer? While not intended to replace standard-of-care, a drug response marker, such as ChemoFX can be valuable in helping you identify treatment choices that are more likely to be effective for your particular cancer patient.
Tumor Drug Response Testing is a fresh tissue platform that uses the patients own live tumor cells to help physicians identify effective treatment options for each gynecologic cancer patient.
Tumor Drug Response Testing was created to help you rule out chemotherapies that don’t work and focus on the ones that are more likely to work—reducing risk to your patient.
Ineffective therapies can lead to:
Tumor drug response testing (ChemoFX) can be used in:
Look inside our live-cell platform.
With Tumor Drug Response Testing, you can personalize your patient’s treatment plan by testing multiple single or combination chemotherapies in the lab before choosing one for your cancer patient.
Demonstrated clinical utility as a prognostic and predictive drug response marker.
- ChemoFx is associated with a 50% improvement in progression-free survival and a 14-month improvement in overall survival when patients receive a sensitive therapy.
- Patients treated with a sensitive agent identified by ChemoFx lived 2.5x longer than patients treated with a resistant agent.
- ChemoFx identifies potentially effective treatments for the majority (59%) of Platinum Resistant Patients.
Select up to 12 drugs or drug combinations, and use your experience and knowledge of each patient to choose a standard panel or design a custom panel. Choosing agents from different drug classes may help you evaluate alternative treatment options for your patients.
Requires a small sample.
The test requires a small tissue sample from surgery. This small sample size allows for less invasive procedures at multiple stages of care. Because cells grow and cycle in culture, Tumor Drug Response Testing ensures enrichment of relevant malignant cells for testing.
Learn about the Tumor Drug Response Testing (formerly ChemoFx) process in this video from within the Helomics lab in Pittsburgh.
The final report
The ChemoFx final report has been specifically designed with physician input to clearly and concisely deliver your patient’s test results.
- Provides information on chemo-sensitivity of available therapies
- Provides results of patient’s individual tumor cell analysis
- Informs treatment strategy and selection
No delay in treatment.
Results are provided within a standard time frame for initiating therapy, enabling you to make critical decisions without delaying treatment. Your patients can get on with their therapy—and more importantly, their lives.
Specifically, the turnaround-time for the ChemoFx test is 28-35 days after the receipt of tissue and all required paperwork, depending on the growth profile of the sample.
Please click the button below to read about the simple process of ordering test kits to be sent to your facility and the required paperwork from you and your patient.